LOWELL, Mass.,
July 7, 2015
/PRNewswire/ -- Alcyone Lifesciences, Inc., a leader in
neural intervention systems for neurological conditions, today
announced that Olivier Danos, Ph.D.,
senior vice president of cell and gene therapy at Biogen
Inc., has joined its Scientific Advisory
Board.
"Dr. Olivier Danos is a
pioneer in the field of gene therapy including for the treatment of
chronic neurological disorders. We are honored to have such a
distinguished scientist as an addition to our Scientific
Advisory Board," stated PJ Anand, chief executive officer and
founder of Alcyone Lifesciences, Inc.
"Optimal delivery is critical and fundamental for
therapeutic efficacy. Alcyone has built an impressive
platform of delivery systems for the central nervous system (CNS)
and is pioneering novel modalities of therapeutic delivery, via
direct delivery and intrathecal approaches," commented Dr.
Olivier Danos. "I am excited to join
this outstanding group of scientist and clinicians on Alcyone's
Scientific Advisory Board."
Dr. Danos leads Biogen's gene therapy research group, a
team dedicated to identifying and developing new technologies for
gene transfer and genome engineering. As part of his role, Dr.
Danos also identifies potential collaborations that complement
Biogen's internal capabilities and supports the development of
treatments across Biogen 's therapeutic focus areas.
Prior to Biogen, Dr. Danos was at Kadmon Pharmaceuticals,
where he served as senior vice president, Molecular Medicine,
Synthetic Biology and Gene Regulation since 2011. In this role, he
was instrumental in assembling a gene therapy program and a
technology platform for the development of controllable gene
expression systems. Prior to Kadmon, Dr. Danos acted as the
director of the Gene Therapy Consortium of the University College
of London and led a gene therapy
research team at the Necker Hospital – Enfants Malades in
Paris.
Dr. Danos is a cofounder and advisor to Lysogene, a
company focused on research and development of gene therapy for
certain neurodegenerative disorders. He has also served as
chief scientific officer at Genethon and senior director of
research at Somatix Therapy Corporation. He has held several senior
roles at the French National Centre for Scientific Research (CNRS)
and at the Institut Pasteur in Paris. Dr. Danos is the former president and a
founding member of the European Society of Gene and Cell
Therapy.
Dr. Danos received a Master's in Genetics and Molecular
Biology at University of Paris
Orsay, and his Ph.D. in Biology at the Pasteur Institute and
University of Paris Diderot.
Also on the Scientific Advisory Board of Alcyone
Lifesciences are:
- William Olbricht PhD., Co-Founder and Professor of Chemical and
Bimolecular Engineering, Cornell
University.
- Adam Fleisher, MD., Co-Founder,
former Director of Imaging, Banner Alzheimer Institute and
Associate Professor of Neurology, UCSD.
- Joseph Madsen, MD., Associate
Professor of Neurosurgery, Harvard Medical
School and Director of Neurodynamics Laboratory and Epilepsy
Program at Boston Children's Hospital
- E. Antonio Chiocca, MD., PhD.,
Chairman of Neurosurgery at Brigham and Women's Hospital and Professor of
Neurosurgery at Harvard Medical
School
- Andres Lozano, MD., PhD, FRCSC,
BmedSci., Chief of Neurosurgery, University of
Toronto and Senior Scientist at Toronto Western
Hospital
- John Laterra, M.D., PhD.,
Director, Division of Neuro-Oncology, Johns
Hopkins University
- David Roberts, MD., Chief of
Neurosurgery, Dartmouth Hitchcock Medical Center, Professor of
Surgery Dartmouth School of Medicine
- Michael Rogawski, MD., PhD.,
Professor of Neurology, University of
California, Davis Campus
- Sangeeta Bhatia, MD., PhD., John
& Dorothy Wilson Professor of Health Sciences and Technology
& Electrical & Computer Science & Director, Laboratory
for Multiscale Regenerative Technologies, Massachusetts Institute of Technology
- Jaime Mata, PhD., Director of
in vivo imaging and Associate Professor, University of Virginia
About Alcyone Lifesciences
Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held
medical device company focused on development of novel treatment
modalities for chronic neurological conditions. The Company's
patented technology platform is based on a uniquely engineered
amalgamation of microfabrication technologies along with advanced
biomedical engineering with core product focus on targeted drug
therapy and hydrocephalus. Alcyone's team of scientists, physicians
and advisers includes recognized leaders in the field of neurology
and neurosurgery. For more information, please visit
www.alcyonels.com
Contacts:
PJ Anand
Chief Executive Officer
info@alcyonels.com
(978) 709-1946
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dr-olivier-danos-cell-and-gene-therapy-pioneer-joins-alcyone-lifesciences-scientific-advisory-board-300109436.html
SOURCE Alcyone Lifesciences, Inc.